Women with ACS receive inferior or less aggressive treatment compared to men

Women with acute coronary syndrome (ACS) receive inferior or less aggressive treatment compared to men, according to three large studies presented today at the World Congress of Cardiology.

The CREATE registry study of 20,468 patients in India revealed that relatively fewer women are admitted with ACS. Moreover, these women are older, reach hospital later, have more risk factors, receive inferior treatments and have worse outcomes.

While the BRIG project study of 3,168 patients in China concluded that a substantial portion of women with ACS did not receive proper treatment during hospitalization compared with men.

Similarly, a study of 4,229 ACS patients in the Middle East found that women tended to be admitted to hospital later than men and had more comorbid disease. These women received commonly used treatments less frequently than men, although in the case of the Middle East study this did not appear to impact in-patient mortality.

"These three studies paint a consistent picture around the world and all serve to demonstrate that women with ACS are unfortunately not receiving the same treatment as men," said Prof. Sidney C Smith Jr, MD, President, World Heart Federation. "This is something that has to be addressed as a matter of urgency."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Tirzepatide improves heart health and function in obese HFpEF patients